Department of Psychiatry, Sheba Medical Center, Tel Hashomer 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Psychiatry, Sheba Medical Center, Tel Hashomer 52621, Israel.
Schizophr Res. 2019 Apr;206:325-332. doi: 10.1016/j.schres.2018.10.023. Epub 2018 Nov 16.
Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial.
We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment. The primary outcome measure was the PANSS total score.
Mixed models for repeated measures showed no significant difference between minocycline and placebo for total PANSS (p = 0.862), PANSS subscales, CGI or BACS.
Minocycline did not improve symptoms or cognition in schizophrenia.
研究表明，免疫异常可能与精神分裂症有关，基础科学研究以及多项临床试验表明，米诺环素可能对改善精神分裂症的阳性和阴性症状有效。本研究旨在通过一项大型随机对照试验，探讨米诺环素对精神分裂症的疗效。
我们对 200 名精神分裂症或分裂情感障碍患者进行了为期 16 周的、多中心的、双盲、随机、安慰剂对照研究，将患者随机分为米诺环素组（200mg/天，n=100）或安慰剂组（n=100），作为抗精神病药物治疗的附加治疗。主要结局指标为 PANSS 总分。
重复测量混合模型显示，米诺环素组与安慰剂组在 PANSS 总分（p=0.862）、PANSS 分量表、CGI 或 BACS 方面无显著差异。
米诺环素不能改善精神分裂症患者的症状或认知功能。
